DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK), 2013.
We would love your feedback. Fill out our anonymous user survey.
On May 29, 2013, the U. S. Food and Drug Administration (FDA) approved trametinib (MEKINIST™ tablets, GlaxoSmithKline, USA), as a single agent oral treatment for patients with non-operable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations as detected by an FDA-approved test, called the THxID™ – BRAF assay from bioMérieux S.A.
Trametinib is the fourth new cancer drug approved that demonstrates an improvement in overall survival in melanoma patients.
It is not indicated for the treatment of patients who have received a prior BRAF inhibitor therapy such as dabrafenib or vemurafenib.
FDA approval was based on results of the phase III METRIC trial.
The most common adverse reactions (greater than or equal to 10%) of any grade in patients receiving trametinib included:
Key efficacy findings are summarised in the tables below.
|Efficacy parameter||Trematinib (n = 214)||Chemotherapy (n = 108)|
|Median progression-free survival (months)||4.8 (95% confidence interval [CI]: 4.3, 4.9)||1.5 (95% CI: 1.4, 2.7)|
|Overall tumour response rates (% patients)||22% (95% CI: 17, 28)||8% (95% CI: 4, 15)|
|Complete response, n (%)||4 (2%)||0|
|Partial response, n (%)||43 (20%)||9 (8%)|
|Median duration of response (months)||5.5 (95% CI: 4.1, 5.9)||Not reached|
|Trematinib (N = 211)||Chemotherapy (N = 99)|
|All Grades||Grades 3 and 4||All Grades||Grades 3 and 4|
|Skin and subcutaneous tissue disorders|
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
Books about skin diseases
© 2022 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.